Antithrombotic CAS 141396-28-3 Argatroban Purity Argatroban Powder API Argatroban

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Argatroban
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Argatroban
• Name: Argatroban Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antithrombotic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 141396-28-3
• Mf: C23h36n6o5s
• MW: 508.638
• Melting Point: 188-189°c
• Density: 1.47
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Antithrombotic CAS 141396-28-3 Argatroban Purity Argatroban Powder API Argatroban

Product Description

Product Details

Product name	Argatroban
Appearance	White powder
CAS NO.	141396-28-3
MF	C23H36N6O5S
MW	508.638

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.In 2000, argatroban was for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.

Argatroban is given intravenously and drug plasma concentrations reach steady state in 1-3 hours. Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

Application&Function

Argatroban is used as an anticoagulant in individuals with thrombosis and heparin induced thrombocytopenia. Often these individuals allenges due to the falsely elevated prothrombin time and INR caused by argatroban. The combination of argatroban and warfari may raise the INR to greater than 5.0 without a significant increased risk of bleeding complications.One solution to this problem is to measure the chromogenic factor X level. A level < 40-45% typically indicates that the INR will be therapeutic (2-3) when the argatroban is discontinued.

Specification